IDH2 and acute myeloid leukemia: Engraftment of AML patient bone marrow cells to immunodeficient mice to create an AML-PDX model, AM7577 (M5 subtype with FLT3-ITD mutation and IDH2 R140Q mutation), is suitable for pharmacological evaluation of new AML targeted drugs, e.g., FLT3/FLT3-ITD inhibitor (FLT3i)1 and IDH2-mutant inhibitor (IDH2muti)2.